2009
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines
Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess K, Baggerly KA, Coombes KR, Pusztai L. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Research And Treatment 2009, 121: 301-309. PMID: 19603265, DOI: 10.1007/s10549-009-0445-7.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCell Line, TumorCyclophosphamideDoxorubicinDrug Resistance, NeoplasmFemaleFluorouracilGene Expression ProfilingHumansNeoplasm StagingOligonucleotide Array Sequence AnalysisPaclitaxelPredictive Value of TestsTreatment OutcomeConceptsBreast cancer cell linesCancer cell linesResponse predictorsBaseline gene expression dataCell linesChemotherapy drugsHuman breast cancer cell linesStandard chemotherapy drugsFine-needle aspiration specimensNeedle aspiration specimensPathologic responseAffymetrix U133A gene chipsClinical evaluationBreast cancerPharmacogenomic predictorsSame drugStage IPredictive valueAspiration specimensMultigene predictorsTumor samplesPatientsResistant cellsPatient dataDrugs
2007
Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer
Pusztai L, Anderson K, Hess KR. Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer. Clinical Cancer Research 2007, 13: 6080-6086. PMID: 17947471, DOI: 10.1158/1078-0432.ccr-07-0809.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsClinical Trials, Phase II as TopicGene Expression ProfilingGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceOligonucleotide Array Sequence AnalysisPharmacogeneticsProbabilityRNA, MessengerTissue DistributionTrastuzumabConceptsPhase II studyPhase II trialII trialII studyBreast cancerTwo-stage phase II trialPhase II clinical trialPhase II trial designPredictors of responseMarker-positive patientsPhase II designUnselected patientsPatient populationClinical trialsTrastuzumab responseInsufficient responseTrial designResponse markersSame drugResponse rateMarker testingPotential predictorsMarker assessmentTrialsPatients